Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Nov;9(11):2474-9.
doi: 10.4161/hv.25814. Epub 2013 Jul 25.

Immunogenicity and safety of hepatitis E vaccine in healthy hepatitis B surface antigen positive adults

Ting Wu  1 , Shou-Jie Huang, Feng-Cai Zhu, Xue-Feng Zhang, Xing Ai, Qiang Yan, Zhong-Ze Wang, Chang-Lin Yang, Han-Min Jiang, Xiao-Hui Liu, Meng Guo, Hai-Lian Du, Mun-Hon Ng, Jun Zhang, Ning-Shao Xia
Affiliations
Randomized Controlled Trial

Immunogenicity and safety of hepatitis E vaccine in healthy hepatitis B surface antigen positive adults

Ting Wu et al. Hum Vaccin Immunother. 2013 Nov.

Abstract

A recombinant hepatitis E vaccine, Hecolin, has been proven safe and effective in healthy adults. As hepatitis B surface antigen (HBsAg) positive individuals have a higher risk of poor prognosis after super-infection with hepatitis E virus (HEV), the safety and immunogenicity of Hecolin in this population should be assessed. The present study is an extending analysis of data from a large randomized controlled clinical trial of Hecolin. Healthy participants (n = 14,065) without current or previous evidence of chronic liver disease were randomized to receive Hecolin or placebo (hepatitis B vaccine) and donated their blood samples before vaccination and subsequently over 31 mo. Most of the adverse events were mild and comparable between participants with and without baseline hepatitis B surface antigen (HBsAg). No vaccine-related serious adverse events were reported. Rates of serious adverse events in HBsAg (+) or HBsAg (-) participants were also comparable between both groups. Almost all participants in the Hecolin group seroconverted to anti-HEV one month after full vaccination. The antibody response rates and levels were similar in HBsAg (+) and HBsAg (-) participants (98.38%, 19.32 Wu/mL vs. 98.69%, 19.00 Wu/mL). The two-year antibody dynamics of HBsAg (+) participants overlapped perfectly with those of HBsAg (-) participants. In conclusion, the safety and immunogenicity of Hecolin for HBsAg (+) adults is very similar to that for the general population.

Keywords: HBsAg; HEV239; Hecolin®; hepatitis E; immunogenicity; safety; vaccine.

PubMed Disclaimer

Figures

None
Figure 1. Trial Profile.
None
Figure 2. Anti-HEV IgG levels of HBsAg (+) and HBsAg (-) participants at month 7 by age. Baseline anti-HEV (-) participants who received all 3 doses of Hecolin® according to the protocol were analyzed. Solid black line: HBsAg (+) participants; solid gray lines: HBsAg (-) participants. 95% confidence intervals (CI) are shown. GMC, geometric mean concentration.
None
Figure 3. Anti-HEV dynamics after Hecolin® vaccination. Participants who received Hecolin® according to the protocol and were tested for anti-HEV at month 0 and month 7 (immunogenicity analysis set) were included. Solid black line: HBsAg (+) participants; dashed gray lines: HBsAg (-) participants. GMC, geometric mean concentration. 95% CI is shown.
See this image and copyright information in PMC

References

    1. Kamar N, Bendall R, Legrand-Abravanel F, Xia NS, Ijaz S, Izopet J, et al. Hepatitis E. Lancet. 2012;379:2477–88. doi: 10.1016/S0140-6736(11)61849-7. - DOI - PubMed
    1. Purcell RH, Emerson SU. Prevention. In: Thomas HC, Lemon S, Zuckerman AJ, eds. Viral hepatitis, 3rd edn. Malden, MA Blackwell Publishing; 2005:635-45.
    1. Dalton HR, Stableforth W, Thurairajah P, Hazeldine S, Remnarace R, Usama W, et al. Autochthonous hepatitis E in Southwest England: natural history, complications and seasonal variation, and hepatitis E virus IgG seroprevalence in blood donors, the elderly and patients with chronic liver disease. Eur J Gastroenterol Hepatol. 2008;20:784–90. doi: 10.1097/MEG.0b013e3282f5195a. - DOI - PubMed
    1. Mizuo H, Yazaki Y, Sugawara K, Tsuda F, Takahashi M, Nishizawa T, et al. Possible risk factors for the transmission of hepatitis E virus and for the severe form of hepatitis E acquired locally in Hokkaido, Japan. J Med Virol. 2005;76:341–9. doi: 10.1002/jmv.20364. - DOI - PubMed
    1. Mansuy JM, Peron JM, Abravanel F, Poirson H, Dubois M, Miedouge M, et al. Hepatitis E in the south west of France in individuals who have never visited an endemic area. J Med Virol. 2004;74:419–24. doi: 10.1002/jmv.20206. - DOI - PubMed

Publication types

MeSH terms